Coronary heart disease in postmenopausal women with type II diabetes mellitus and the impact of estrogen replacement therapy: A narrative review

International Journal of Endocrinology

Volumn 2014, Issue , 2014, Pages

  Boukhris, Marouane ^a   Tomasello, Salvatore Davide ^a   Marzà, Francesco ^a   Bregante, Sonia ^b   Pluchinotta, Francesca Romana ^b   Galassi, Alfredo Ruggero ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b IRCCS POLICLINICO SAN DONATO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; HEMOGLOBIN A1C;

ABDOMINAL OBESITY; AGE; BODY MASS; CARDIOVASCULAR EFFECT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE ASSOCIATION; DYSLIPIDEMIA; ESTROGEN THERAPY; FEMALE; HEART PROTECTION; HUMAN; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; SEDENTARY LIFESTYLE; SMOKING;

EID: 84928503856     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2014/413920     Document Type: Review

References (83)

1. P. A. Wingo, E. E. Calle, and A. McTiernan, "How does breast cancer mortality compare with that of other cancers and selected cardiovascular diseases at different ages in U.S. women?" Journal of Women's Health and Gender-Based Medicine, vol. 9, no. 9, pp. 999-1006, 2000.
2. W. Rosamond, K. Flegal, K. Furie et al., "Heart disease and stroke statistics-2008 update: A report from the American heart association statistics committee and stroke statistics subcommittee," Circulation, vol. 117, no. 4, pp. e25-e46, 2008.
3. W. B. Kannel and P. W. F. Wilson, "Risk factors that attenuate the female coronary disease advantage," Archives of Internal Medicine, vol. 155, no. 1, pp. 57-61, 1995.
4. S. M. Haffner, S. Lehto, T. Rönnemaa, K. Pyörälä, and M. Laakso, "Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction,"The New England Journal of Medicine, vol. 339, no. 4, pp. 229-234, 1998.
5. A. R. Galassi, S. D. Tomasello, F. Crea et al., "Transient impairment of vasomotion function after successful chronic total occlusion recanalization," Journal of the American College of Cardiology, vol. 59, no. 8, pp. 711-718, 2012.
6. F. Ledru, P. Ducimetìere, S. Battaglia et al., "New diagnostic criteria for diabetes and coronary artery disease: Insights from an angiographic study," Journal of the American College of Cardiology, vol. 37, no. 6, pp. 1543-1550, 2001.
7. R. Huxley, F. Barzi, and M. Woodward, "Excess risk of fatal coronary heart disease associated with diabetes in men and women: Meta-analysis of 37 prospective cohort studies," British Medical Journal, vol. 332, no. 7533, pp. 73-78, 2006.
8. A. Juutilainen, S. Kortelainen, S. Lehto, T. Rönnemaa, K. Pyörälä, and M. Laakso, "Gender difference in the impact of type 2 diabetes on coronary heart disease risk," Diabetes Care, vol. 27, no. 12, pp. 2898-2904, 2004.
9. F. Grodstein, M. J. Stampfer, J. E. Manson et al., "Postmenopausal estrogen and progestin use and the risk of cardiovascular disease,"TheNew England Journal ofMedicine, vol. 335, no. 7, pp. 453-461, 1996.
10. J. E. Rossouw, G. L. Anderson, R. L. Prentice et al., "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial," Journal of the American Medical Association, vol. 288, no. 3, pp. 321-333, 2002.
11. S.Hulley,D.Grady, T. Bush et al., "Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausalwomen,"TheJournal of theAmerican Medical Association, vol. 280, no. 7, pp. 605-613, 1998.
12. M. I. Harris, K. M. Flegal, C. C. Cowie et al., "Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: The Third National Health and Nutrition Examination Survey, 1988-1994," Diabetes Care, vol. 21, no. 4, pp. 518-524, 1998.
13. D. L. Wingard and E. Barrett-Connor, "Heart disease and diabetes," in Diabetes in America, M. I. Harris, C. C. Courie, G. Beiber, E. Boyko,M. Stern, andP.Bennet, Eds.,NIHPublication No. 95-1468, US Government Printing Office,Washington, DC, USA, 2nd edition, 1995.
14. R. J.Goldberg,M. Larson, andD. Levy, "Factors associatedwith survival to 75 years of age in middle-aged men and women: The Framingham study," Archives of Internal Medicine, vol. 156, no. 5, pp. 505-509, 1996.
15. W. B. Kannel and D. L. McGee, "Diabetes and cardiovascular disease. The Framingham study," The Journal of the American Medical Association, vol. 241, no. 19, pp. 2035-2038, 1979.
16. P. Greenland,H. Reicher-Reiss,U.Goldbourt, and S. Behar, "Inhospital and 1-year mortality in 1,524 women after myocardial infarction. Comparison with 4,315 men," Circulation, vol. 83,no. 2, pp. 484-491, 1991.
17. E. Barrett-Connor and T. L. Bush, "Estrogen and coronary heart disease in women," The Journal of the American Medical Association, vol. 265, no. 14, pp. 1861-1867, 1991.
18. M. Laakso, "Glycemic control and the risk for coronary heart disease in patients with non-insulin-dependent diabetes mellitus: The Finnish studies," Annals of Internal Medicine, vol. 124, no. 1, pp. 127-130, 1996.
19. J. R. Sowers, "Obesity and cardiovascular disease," Clinical Chemistry, vol. 44, no. 8, pp. 1821-1825, 1998.
20. J. M. Olefsky, J. W. Farquhar, and G. M. Reaven, "Reappraisal of the role of insulin in hypertriglyceridemia," The American Journal of Medicine, vol. 57, no. 4, pp. 551-560, 1974.
21. M. H. Cummings, G. F.Watts, A.M. Umpleby et al., "Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM," Diabetologia, vol. 38, no. 8, pp. 959-967, 1995.
22. R. Frénais, K. Ouguerram, C. Maugeais et al., "High density lipoprotein apolipoprotein AI kinetics in NIDDM: A stable isotope study," Diabetologia, vol. 40, no. 5, pp. 578-583, 1997.
23. R. D. Siegel, A. Cupples, E. J. Schaefer, and P. W. F. Wilson, "Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham offspring study," Metabolism: Clinical and Experimental, vol. 45, no. 10, pp. 1267-1272, 1996.
24. D. J. Schneider, T. K. Nordt, and B. E. Sobel, "Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients," Diabetes, vol. 42, no. 1, pp. 1-7, 1993.
25. S. H. J. Donders, F. A. T. Lustermans, and J. W. J. Van Wersch, "The effect of microalbuminuria on glycaemic control, serum lipids and haemostasis parameters in non-insulin-dependent diabetes mellitus," Annals of Clinical Biochemistry, vol. 30, no. 5, pp. 439-444, 1993.
26. W. B. Kannel, R. B. D'Augustino, and A. J. Belanger, "Update on fibrinogen as a cardiovascular risk factor," Annals of Epidemiology, vol. 2, no. 4, pp. 457-466, 1993.
27. P.M.Ridker, D. E. Vaughan,M. J. Stampfer, J.E.Manson, andC. H. Hennekens, "Endogenous tissue-type plasminogen activator and risk ofmyocardial infarction,"TheLancet, vol. 341, no. 8854, pp. 1165-1168, 1993.
28. A. J. Lee, G. D. O. Lowe,W. C. S. Smith, and H. Tunstall-Pedoe, "Plasma fibrinogen inwomen: Relationship with oral contraception, the menopause and hormone replacement therapy," The British Journal of Haematology, vol. 83, no. 4, pp. 616-621, 1993.
29. U. H. Winkler, "Menopause, hormone replacement therapy and cardiovascular disease: A review of haemostaseological findings," Fibrinolysis, vol. 6, no. 3, pp. 5-10, 1992.
30. L. Balteskard, J. H. Brox, and B. Osterud, "Thromboxane production in the blood of women increases after menopause whereas tumor necrosis factor is reduced in women compared with men," Atherosclerosis, vol. 102, no. 1, pp. 91-98, 1993.
31. A. O. Mueck and H. Seeger, "Effect of hormone therapy on BP in normotensive and hypertensive postmenopausalwomen," Maturitas, vol. 49, no. 3, pp. 189-203, 2004.
32. C. S. Hayward, K. Samaras, L. Campbell, and R. P. Kelly, "Effect of combination hormone replacement therapy on ambulatory blood pressure and arterial stiffness in diabetic postmenopausal women," American Journal of Hypertension, vol. 14, no. 7, part 1, pp. 699-703, 2001.
33. S. D. Spandorfer, "Cigarette smoking in the menopausal woman," Primary Care Update for Ob/Gyns, vol. 3, no. 6, pp. 212-215, 1996.
34. C. A. Oncken, W. B. White, J. L. Cooney, J. R. Van Kirk, J. S. Ahluwalia, and S. Giacco, "Impact of smoking cessation on ambulatory blood pressure and heart rate in postmenopausal women,"The American Journal of Hypertension, vol. 14, no. 9 I, pp. 942-949, 2001.
35. E. Falk, P. K. Shah, and V. Fuster, "Coronary plaque disruption," Circulation, vol. 92, no. 3, pp. 657-671, 1995.
36. R.O. Cannon III, "Role of nitric oxide in cardiovascular disease: Focus on the endothelium," Clinical Chemistry, vol. 44, no. 8, part 2, pp. 1809-1819, 1998.
37. G. M. C. Rosano, P. Collins, J. C. Kaski, D. C. Lindsay, P. M. Sarrel, and P. A. Poole-Wilson, "Syndrome X in women is associated with oestrogen deficiency," European Heart Journal, vol. 16, no. 5, pp. 610-614, 1995.
38. M. Turiel, A. R. Galassi, J. J. Glazier, J. C. Kaski, and A.Maseri, "Pain threshold and tolerance in women with syndrome X and women with stable angina pectoris," The American Journal of Cardiology, vol. 60, no. 7, pp. 503-507, 1987.
39. J. E. Tamis-Holland, J. Lu, M. Korytkowski et al., "Sex differences in presentation and outcome among patients with type 2 diabetes and coronary artery disease treatedwith contemporary medical therapy with or without prompt revascularization: A report from the BARI 2D trial (Bypass Angioplasty Revascularization Investigation 2 Diabetes)," Journal of the American College of Cardiology, vol. 61, no. 17, pp. 1767-1776, 2013.
40. S. Ahmad, Z. Xue, A. Silverman, and J. Lindsay, "Complexity of the relation between hemoglobin A1C, diabetes mellitus, and progression of coronary narrowing in postmenopausalwomen," The American Journal of Cardiology, vol. 111, no. 6, pp. 793-799, 2013.
41. S. F. Kelsey, M. James, A. L. Holubkov, R. Holubkov, M. J. Cowley, and K. M.Detre, "Results of percutaneous transluminal coronary angioplasty in women: 1985-1986 National Heart, Lung, and Blood Institute's Coronary Angioplasty Registry," Circulation, vol. 87, no. 3, pp. 720-727, 1993.
42. M. R. Bell, D. R. Holmes Jr., P. B. Berger, K. N. Garratt, K. R. Bailey, and B. J. Gersh, "The changing in-hospital mortality of women undergoing percutaneous transluminal coronary angioplasty," The Journal of the American Medical Association, vol. 269, no. 16, pp. 2091-2095, 1993.
43. F. Zijlstra, J. C. A. Hoorntje, M. De Boer et al., "Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction," The New England Journal of Medicine, vol. 341, no. 19, pp. 1413-1419, 1999.
44. G. W. Stone, C. L. Grines, D. A. Cox et al., "For the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting with or without abciximab, in acute myocardial infarction," The New England Journal of Medicine, vol. 346, pp. 957-966, 2002.
45. S. E. Capes, D. Hunt, K. Malmberg, and H. C. Gerstein, "Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: A systematic overview," The Lancet, vol. 355, no. 9206, pp. 773-778, 2000.
46. A. Porter, A. R. Assali, A. Zahalka et al., "Impaired fasting glucose and outcomes of ST-elevation acute coronary syndrome treatedwith primary percutaneous intervention among patients without previously known diabetes mellitus," The American Heart Journal, vol. 155, no. 2, pp. 284-289, 2008.
47. G. De Luca, C. M. Gibson, F. Bellandi et al., "Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors," Atherosclerosis, vol. 207, no. 1, pp. 181-185, 2009.
48. C. Tamburino, D. J. Angiolillo, P. Capranzano et al., "Complete versus incomplete revascularization in patients withmultivessel disease undergoing percutaneous coronary intervention with drug-eluting stents," Catheterization and Cardiovascular Interventions, vol. 72, no. 4, pp. 448-456, 2008.
49. F. Prati, S. Petronio, A. J. Van Boven et al., "Evaluation of infarctrelated coronary artery patency and microcirculatory function after facilitated percutaneous primary coronary angioplasty: The FINESSE-ANGIO (Facilitated Intervention with Enhanced Reperfusion Speed to Stop EventsAngiographic) study," JACC: Cardiovascular Interventions, vol. 3, no. 12, pp. 1284-1291, 2010.
50. P. Buja, G. D'Amico, M. Facchin et al., "Gender-related differences of diabetic patients undergoing percutaneous coronary intervention with drug-eluting stents: A real-life multicenter experience," International Journal of Cardiology, vol. 168, no. 1, pp. 139-143, 2013.
51. M. Capdeville, J. H. Lee, and A. L. Taylor, "Effect of gender on fast-track recovery after coronary artery bypass graft surgery," Journal of Cardiothoracic and Vascular Anesthesia, vol. 15, no. 2, pp. 146-151, 2001.
52. K. R. Dimitrova, D. M. Hoffman, C. M. Geller et al., "Radial artery grafting in women improves 15-year survival," Journal of Thoracic and Cardiovascular Surgery, vol. 146, no. 6, pp. 1467-1473, 2012.
53. P. Collins and C. Beale, The Cardioprotective Role of HRT: A Clinical Update, vol. 14, chapter 2, Parthenon, New York, NY, USA, 1996.
54. R. Ross, "Atherosclerosis: An inflammatory disease," The New England Journal of Medicine, vol. 340, no. 2, pp. 115-126, 1999.
55. C. H. Selzman, S. A. Miller, and A. H. Harken, "Therapeutic implications of inflammation in atherosclerotic cardiovascular disease," Annals of Thoracic Surgery, vol. 71, no. 6, pp. 2066-2074, 2001.
56. J. J. A. M.Weusten, M. A. Blankenstein, F. H. J.Gmelig-Meyling, H. J. Schuurman, L. Kater, and J. H. Thijssen, "Presence of oestrogen receptors in human blood mononuclear cells and thymocytes," Acta Endocrinologica, vol. 112, no. 3, pp. 409-414, 1986.
57. R. Pacifici, C. Brown, E. Puscheck et al., "Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 12, pp. 5134-5138, 1991.
58. B. Aune, P. ∅ian, I. Omsjø, and B. ∅sterud, "Hormone replacement therapy reduces the reactivity of monocytes and platelets in whole blood-a beneficial effect on atherogenesis and thrombus formation?" American Journal of Obstetrics and Gynecology, vol. 173, no. 6, pp. 1816-1820, 1995.
59. M. Kamada, M. Irahara, M. Maegawa et al., "Postmenopausal changes in serum cytokine levels and hormone replacement therapy," American Journal of Obstetrics and Gynecology, vol. 184, no. 3, pp. 309-314, 2001.
60. B.W.Walsh, I. Schiff, B. Rosner, L. Greenberg, V. Ravnikar, and F. M. Sacks, "Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins," The New England Journal of Medicine, vol. 325, no. 17, pp. 1196-1204, 1991.
61. A. A. Nabulsi, A. R. Folsom, A. White et al., "Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women,"The New England Journal of Medicine, vol. 328, no. 15, pp. 1069-1075, 1993.
62. G. M. Fischer and M. L. Swain, "Effects of estradiol and progesterone on the increased synthesis of collagen in atherosclerotic rabbit aortas," Atherosclerosis, vol. 54, no. 2, pp. 177-185, 1985.
63. T. W. Meade, A. P. Haines, J. D. Imeson, Y. Stirling, and S. G. Thompson, "Menopausal status and haemostatic variables," The Lancet, vol. 1, no. 8314, pp. 22-24, 1983.
64. M.Nozaki, R. Ogata, K. Koera, K. Hashimoto, and H. Nakano, "Changes in coagulation factors and fibrinolytic components of postmenopausal women receiving continuous hormone replacement therapy," Climacteric, vol. 2, no. 2, pp. 124-130, 1999.
65. M. Cushman, C. Legault, E. Barrett-Connor et al., "Effect of postmenopausal hormones on inflammation-sensitive proteins: The Postmenopausal Estrogen/Progestin Interventions (PEPI) study," Circulation, vol. 100, no. 7, pp. 717-722, 1999.
66. K. K. Koh, R. Mincemoyer, M. N. Bui et al., "Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women,"The New England Journal ofMedicine, vol. 336, no. 10, pp. 683-690, 1997.
67. Y. G. Caine, K. A. Bauer, S. Barzegar et al., "Coagulation activation following estrogen administration to postmenopausal women," Thrombosis and Haemostasis, vol. 68, no. 4, pp. 392-395, 1992.
68. P.-Y. Scarabin, M. Alhenc-Gelas, G. Plu-Bureau, P. Taisne, R. Agher, and M. Aiach, "Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women: A randomized controlled trial," Arteriosclerosis,Thrombosis, and Vascular Biology, vol. 17, no. 11, pp. 3071-3078, 1997.
69. S. J. Lee, D.W. Lee, K. S. Kim, and I. K. Lee, "Effect of estrogen on endothelial dysfunction in postmenopausal women with diabetes," Diabetes Research and Clinical Practice, vol. 54, no. 2, pp. S81-S92, 2001.
70. C. R. Triggle and H. Ding, "A review of endothelial dysfunction in diabetes: A focus on the contribution of a dysfunctional eNOS," Journal of the American Society of Hypertension, vol. 4, no. 3, pp. 102-115, 2010.
71. E. H. Lieberman, M. D. Gerhard, A. Uehata et al., "Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women," Annals of Internal Medicine, vol. 121, no. 12, pp. 936-941, 1994.
72. H. Tagawa,H. Shimokawa, T. Tagawa,M. Kuroiwa-Matsumoto, Y. Hirooka, and A. Takeshita, "Short-term estrogen augments both nitric oxide-mediated and non-nitric oxidemediated endothelium-dependent forearm vasodilation in postmenopausal women," Journal of Cardiovascular Pharmacology, vol. 30, no. 4, pp. 481-488, 1997.
73. D. E. Bush, C. E. Jones, K. M. Bass, G. K.Walters, J.M. Bruza, and P. Ouyang, "Estrogen replacement reverses endothelial dysfunction in postmenopausal women," American Journal of Medicine, vol. 104, no. 6, pp. 552-558, 1998.
74. K. K. Koh, M. H. Kang, D. K. Jin et al., "Vascular effects of estrogen in type II diabetic postmenopausal women," Journal of the American College of Cardiology, vol. 38, no. 5, pp. 1409-1415, 2001.
75. F. Squadrito, D. Altavilla, G. Squadrito et al., "17-oestradiol reduces cardiac leukocyte accumulation in myocardial ischaemia reperfusion injury in rat," European Journal of Pharmacology, vol. 335, no. 2-3, pp. 185-192, 1997.
76. A. Negre-Salvayre, M. Pieraggi, L. Mabile, and R. Salvayre, "Protective effect of 17-estradiol against the cytotoxicity of minimally oxidized LDL to cultured bovine aortic endothelial cells," Atherosclerosis, vol. 99, no. 2, pp. 207-217, 1993.
77. V. A. Rifici and A. K. Khachadurian, "The inhibition of lowdensity lipoprotein oxidation by 17- estradiol," Metabolism: Clinical and Experimental, vol. 41, no. 10, pp. 1110-1114, 1992.
78. H. Sumino, S. Ichikawa, T. Kanda et al., "Hormone replacement therapy in postmenopausal women with essential hypertension increases circulating plasma levels of bradykinin," American Journal of Hypertension, vol. 12, no. 10, pp. 1044-1047, 1999.
79. P. Collins, G. M. C. Rosano, C. Jiang, D. Lindsay, P. M. Sarrel, and P. A. Poole-Wilson, "Cardiovascular protection by oestrogen: A calcium antagonistic effect?" The Lancet, vol. 341, no. 8855, pp. 1264-1265, 1993.
80. C. Jiang, P. M. Sarrel, D. C. Lindsay, P. A. Poole-Wilson, and P. Collins, "Endothelium-independent relaxation of rabbit coronary artery by 17-oestradiol in vitro," British Journal of Pharmacology, vol. 104, no. 4, pp. 1033-1037, 1991.
81. A. Cano and W. M. Van Baal, "The mechanisms of thrombotic risk induced by hormone replacement therapy," Maturitas, vol. 40, no. 1, pp. 17-38, 2001.
82. A. Ferrara, C. P. Quesenberry, A. J. Karter, C.W. Njoroge, A. S. Jacobson, and J. V. Selby, "Current use of unopposed estrogen and estrogen plus progestin and the risk of acute myocardial infarction among women with diabetes: The Northern California Kaiser Permanente Diabetes Registry, 1995-1998," Circulation, vol. 107, no. 1, pp. 43-48, 2003.
83. L. L. Humphrey, B. K. Chan, and H. C. Sox, "Postmenopausal hormone replacement therapy and the primary prevention of cardiac vascular," Annals of Internal Medicine, vol. 137, pp. 272-284, 2002.